HBOT Conversations:
Laurie Anderson (Part 1)

Healing COVID with HBOT

Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF).  Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center.  For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.

Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing.  She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health.  Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach. She discovered HBOT when she was struggling to heal from COVID, and now tells anyone who will listen about the power of oxygen and pressure.

Subscribe. Join the discussion. Share the hope.

Watch the Podcast

We are thrilled to have Dr. Laurie Anderson join us at the HBOT News Network. Dr. Laurie used Hyperbaric Oxygen Therapy to heal from a very serious COVID illness.

Dr. Laurie explains her background to the audience and that she received treatment in Raleigh, NC at the Extivita clinic. Her background is important and intriguing.  Dr. Laurie is a Pharmacist by training, a PharmD. While she has done some clinical work in the past, her passion lies in the safety of clinical studies. She focuses on early phase clinical study work, designing risk mitigation strategies for first time in human studies. Dr. Laurie explained that in her line of work she looks at the risk profile of the assets coming out, the design risk mitigation strategies, and then follows them in the clinic to track them to help ensure that they know what’s safe and what isn’t. Essentially, she is part of the team that helps determine if certain drugs are safe and effective.

di Girolamo explains that when he first started looking at hyperbarics, he was personally trying to understand if it was indeed safe and effective.  He found that it was, and was blown away that everyone wasn’t using it. This opened the door to Dr. Laurie telling her story of COVID healing with HBOT, and what led her to Extivita.

Dr. Laurie explains that she has a history of lyme diesease, and worked really hard not to get COVID in fear that she would struggle with complete healing.  She had been vaccinated and boostered, and when she did get COVID she became very ill. In addition to losing her sense of smell and taste, she had a relentless cough, really awful fatigue, and some shortness of breath that that just wasn’t improving.  She ended up on medical leave because she could not work, and when she started to reach the end of the medical leave she still was not improving. Dr. Laurie talked to the naturopath who had been following her for many years, and her naturopath suggested NAD infusions. Dr. Laurie had never heard of NAD infusions before, so she started to read about them and who does them locally in the Raleigh, NC area.  That’s when Dr. Laurie was introduced to the Extivita clinic.

Dr. Laurie came to Extivita to start NAD infusions, but was also encouraged to try Hyperbaric Oxygen Therapy to heal from COVID.  The clinic explained that they are seeing really great success using hyperbarics for COVID long-hauler patients. Dr. Laurie was hesitant due to her claustrophobia, but in the end she decided it was worth a try.  She educated herself on HBOT, and found that there wasn’t a reason why she shouldn’t do it.  She was desperate to heal from the COVID infection. So, she committed to 20 dives, 4 days a week and had phenomenal results; claiming significant improvement after only ten dives.

“I got to say, I was kind of blown away because I had been battling with no improvement for long enough to be concerned, and I came in and I think it was about maybe five or six dives in, and my taste and smell started returning. It was completely gone. And I started to see a change probably in maybe eight, nine or ten, that my cough started going away. I would say by 12 or 13 dives, I felt healed, I felt recovered and even better than I felt going in [the way I felt before getting COVID].”

Dr. Laurie exclaimed that she noticed a positive difference in her energy and sleep almost immediately.  She was more restful, and she said she pays close attention to those things because her history with chronic illness.

“I just could tell a difference. And in my energy, mainly. My energy level and my sleep really shifted, which was a real gift.”

Dr. Laurie even shared her story in an Extivita testimonal, hopeful that others can also discover the powerful combination of oxygen and pressure to heal from COVID.

 

Stay tuned next week for Part 2 of Dr. Laurie’s podcast. We will talk with her about some other benefits of HBOT, and we’ll pick her brain on clinical trials involving hyperbaric oxygen therapy.

 

Guests

Elena Schertz, NP

Dr. Laurie Anderson, Pharm.D.

Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF).  Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center.  For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.

Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing.  She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health.  Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach.

When not working, Dr. Laurie is an avid gardener, ballroom dancer and traveler with her husband. Remaining curious and finding joy in every day are her super powers.

Subscribe Now, It’s Free!

[contact-form-7 id="65934" title="Subscribe"]

Recent HBOT News

Cerebral hypoperfusion in autism spectrum disorder

Cerebral hypoperfusion, or insufficient blood flow in the brain, occurs in many areas of the brain in patients diagnosed with autism spectrum disorder (ASD). Hypoperfusion was demonstrated in the brains of individuals with ASD when compared to normal healthy control brains either using positron emission tomography (PET) or single‑photon emission computed tomography (SPECT). The affected areas include, but are not limited to the: prefrontal, frontal, temporal, occipital, and parietal cortices; thalami; basal ganglia; cingulate cortex; caudate nucleus; the limbic system including the hippocampal area; putamen; substantia nigra; cerebellum; and associative cortices. Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an ASD were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain. Evidence suggests that brain inflammation and vascular inflammation may explain a part of the hypoperfusion. There is also evidence of a lack of normal compensatory increase in blood flow when the subjects are challenged with a task. Some studies propose treatments that can address the hypoperfusion found among individuals diagnosed with an ASD, bringing symptom relief to some extent. This review will explore the evidence that indicates cerebral hypoperfusion in ASD, as well as the possible etiological aspects, complications, and treatments.

Clinical Trial – Spinal Anesthesia in Caesarean Section

Spinal anesthesia is a safe technique, widely used and tested in the gynecological field, so
as to be considered the first choice technique in cesarean section, which allows to quickly
obtain a valid sensor and motor block. Bupivacaine is one of the most widely used drug for
obtaining spinal anesthesia in pregnant women undergoing caesarean section. Bupivacaine is a
local anesthetic available as a racemic mixture of its two enantiomers, the R (+)-
dextrobupivacaine and the S (-) – levobupivacaine, whose clinical use is widely validated.
Racemic bupivacaine is available as a simple or hyperbaric solution, the latter being the
most commonly used for spinal anesthesia. Levobupivacaine, which is the pure levorotatory
enantiomer of racemic bupivacaine, is a slightly hypobaric solution compared to liquor and
has shown less heart and nerve toxicity, probably due to its ability to bind proteins more
rapidly, and a greater selectivity towards the sensory component compared to Bupivacaine,
presents action and effects better predictable. Its baricity would also offer the advantage
of providing a less sensitive block to the position.

Hypotension is one of the most common complications of spinal anesthesia and is particularly
relevant in caesarean section because, in addition to the adverse effects on the parturient,
it can have repercussions on the fetus through a reduction of placental perfusion.

Some studies have showed a similar incidence of hypotension in patients treated with
bupivacaine compared to those treated with levobupivacaine, while others assert an
equivalence between the two drugs. In most studies, however, a significantly lower incidence
of hypotension and a greater hemodynamic stability were reported in pregnant patients
undergoing spinal anesthesia by caesarean section with levobupivacaine.

Being both hyperbaric bupivacaine and levobupivacaine routinely used at the "G. Rodolico"
Universitary Hospital of Catania for the spinal anesthesia of pregnant women undergoing
caesarean section and being their use decided exclusively at discretion of the treating
anesthesiologist, in the light of the discrepant data in the literature about the incidence
of hypotension with the two drugs, the main objective of this observational study is to
evaluate the hemodynamic effects mediated by levobupivacaine on pregnant women subjected to
elective cesarean section and to compare them with those mediated by hyperbaric bupivacaine
in an historical court of pregnant women subjected to caesarean section in the period between
April 2017 and April 2018. The hemodynamic parameters will be monitored in real time with a
non-invasive hemodynamic monitoring system (EV1000® platform + Clearsight® system – Edwards
LifeSciences), routinely used in the "G. Rodolico" Universitary Hospital of Catania, allowing
to obtain greater accuracy and veracity of the results compared to previous studies conducted
on such anesthetics.